版本:
中国

BRIEF-Biotest says Immunogen not to exercise late stage co-development option for US-market with Biotest's antibody-drug conjugate

March 24 Biotest AG:

* Immunogen has elected not to exercise its late stage co-development option for the us-market with Biotest's antibody-drug conjugate (BT-062) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐